Akeso Celebrates a New Milestone in Cancer Therapy
HONG KONG – Akeso, Inc. (9926.HK) has announced a significant achievement in its innovative cancer treatment journey. The company's bispecific antibody, ivonescimab, has received its fifth Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). This noteworthy designation is particularly for the use of ivonescimab combined with chemotherapy as a first-line treatment for advanced biliary tract cancer.
The Impact of Breakthrough Therapy Designation
This recent accolade marks not only a pivotal moment for Akeso but confirms the therapeutic promise of ivonescimab. Previously, ivonescimab had already secured designations for its efficacy against lung cancer and triple-negative breast cancer. The consistent recognition from the NMPA highlights the drug's extensive clinical potential across various cancers where treatment options are still limited.
Clinical Study Insights
Currently, a robust randomized Phase III clinical trial, designated AK112-309/HARMONi-GI1, is underway. This study directly compares the effectiveness of ivonescimab paired with chemotherapy against durvalumab, another treatment option, for patients with advanced biliary tract cancer. Enrollment for this trial has been completed, and with the latest Breakthrough Therapy Designation, Akeso aims to expedite both clinical development and regulatory reviews in the region.
Encouraging Results from Recent Research
Recent findings showcased during the American Society of Clinical Oncology (ASCO) Annual Meeting reveal promising results for the ivonescimab combination therapy. With an impressive Objective Response Rate (ORR) of 63.6% and a remarkable Disease Control Rate (DCR) of 100%, the results certainly bolster the case for ivonescimab as a leading contender in first-line cancer treatment. Furthermore, this therapy has demonstrated a median Progression-Free Survival (mPFS) of 8.5 months alongside a median Overall Survival (mOS) of 16.8 months, presenting a compelling argument for its clinical use.
Addressing Healthcare Needs
The results from the Phase II trials lay a robust groundwork for the ongoing Phase III study. As advanced biliary tract cancer continues to pose significant treatment challenges, ivonescimab offers hope for patients whose current options are often ineffective for achieving lasting results.
About Akeso's Innovative Journey
Founded in 2012, Akeso (HKEX: 9926.HK) has emerged as a leader in the biopharmaceutical field. The company is dedicated to not only developing but also manufacturing and commercializing first or best-in-class innovative medical solutions. Central to its success is a proprietary Tetrabody bispecific antibody platform, along with ADC (Antibody-Drug Conjugate) technologies, and numerous other methodologies in cell therapy and RNA modalities.
Comprehensive Pipeline of Solutions
In recent years, Akeso has cultivated an extensive and innovative pipeline exceeding 50 therapeutic assets, primarily targeting cancer and autoimmune diseases. Among these, 26 candidates are currently undergoing clinical trials, showcasing the company's vast potential for future breakthroughs.
Continuing to Innovate
As Akeso forges ahead in biopharmaceutical innovation, the company is committed to harnessing global resources to create effective therapeutic antibodies. Its mission is not only to provide cutting-edge medical solutions but also to deliver affordable treatments that can significantly improve patient outcomes worldwide.
Frequently Asked Questions
What is the significance of the fifth Breakthrough Therapy Designation?
This designation highlights the clinical promise of ivonescimab in treating advanced biliary tract cancer, expediting its development and review process.
How does ivonescimab work?
Ivonescimab is a bispecific antibody that targets PD-1 and VEGF, potentially enhancing the immune system's response to cancer.
What are the results of the recent studies on ivonescimab?
The studies show an outstanding Objective Response Rate of 63.6% and a Disease Control Rate of 100% with promising survival rates.
What types of cancer has ivonescimab been designated for?
Ivonescimab has received designations for advanced biliary tract cancer, lung cancer, and triple-negative breast cancer.
What is Akeso's mission in the biopharmaceutical industry?
Akeso aims to develop and provide innovative, affordable biopharmaceutical solutions to address significant healthcare needs globally.
